Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Initial Treatment of Acute GVHD (BMT CTN 0302)
NCT00224874Phase 2Completed
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Sep 2005
- Primary completion
- Jan 2009
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of etanercept, mycophenolate mofetil, denileukin diftitox, pentostatin in Acute Graft-Versus-Host Disease (aGvHD), sponsored by National Heart, Lung, and Blood Institute. Started Sep 2005; status: completed.
02
Drugs
etanerceptmycophenolate mofetildenileukin diftitoxpentostatin
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT00224874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00224874.